Related Experiment Videos
[Perennial allergic rhinitis. Prophylaxis of acute episodes using thymomodulin]
R Marzari1, P Mazzanti, P Cazzola
1Università degli Studi di Bologna, Istituto di Clinica Otorinolaringologica.
Minerva Medica
|November 30, 1987
Summary
Thymomodulin, a calf thymic derivative, significantly reduced allergic rhinitis episodes and symptoms in patients. This oral treatment also normalized IgE levels and decreased allergy test scores.
Area of Science:
- Immunology
- Allergology
- Pharmacology
Context:
- Perennial allergic rhinitis is a chronic condition impacting quality of life.
- Current treatments may have limitations or side effects.
- Investigating novel immunomodulatory agents is crucial.
Purpose:
- To evaluate the therapeutic effectiveness of thymomodulin in patients with perennial allergic rhinitis.
Summary:
- A 4-month oral administration of thymomodulin (120 mg daily) in 20 patients.
- Significant reduction in monthly mean frequency of allergic episodes (p < 0.001).
- Improvement in objective symptoms (p < 0.05), normalization of IgE (p < 0.001), decreased RAST/PRICK scores (p < 0.001), reduced eosinophils (p < 0.001), and increased IgG (p < 0.02).
Impact:
- Thymomodulin demonstrates significant clinical and immunological benefits for allergic rhinitis.
- Potential as an effective oral therapeutic option for managing allergic rhinitis.
- Highlights the role of thymic derivatives in modulating allergic responses.